Tag: PCI

Latest News

PCI Pharma Services Announces Major Investment to Expand Development and Manufacturing Capabilities at Tredegar, UK Site

Newsemia
PHILADELPHIA–(BUSINESS WIRE)–PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, today announced it has begun an expansion of its Tredegar facility...
Cardiology

Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries.

Newsemia
Related Articles Average daily ischemic versus bleeding risk in patients with ACS undergoing PCI: Insights from the BleeMACS and RENAMI registries. Am Heart J. 2019...
Latest News

 Subgroup Analysis of TWILIGHT Trial Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Who Underwent PCI Showed BRILINTA Monotherapy Reduced the Risk of Clinically Relevant Bleeding Compared With Dual Antiplatelet Therapy (DAPT)

Newsemia
WILMINGTON, Del.–(BUSINESS WIRE)–New results from a pre-specified subgroup analysis of the TWILIGHT trial showed that BRILINTA (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding...
Latest News

IDEAL LM study: Biodegradable polymer everolimus-eluting stent is safe, effective for patients undergoing PCI

Newsemia
New data from the IDEAL-LM trial found that a biodegradable polymer everolimus-eluting stent (BP-EES) followed by four months of dual antiplatelet therapy (DAPT) was safe...
Latest News

Shorter duration DAPT after PCI did not increase adverse events in high-bleeding risk patients, finds study

Newsemia
Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy did not increase myocardial infarction or stent thrombosis in high bleeding...
Cardiology

The role of Glucagon-Like Peptide 1 Loading on periprocedural myocardial infarction During elective PCI (GOLD-PCI study): A randomized, placebo-controlled trial.

Newsemia
Related Articles The role of Glucagon-Like Peptide 1 Loading on periprocedural myocardial infarction During elective PCI (GOLD-PCI study): A randomized, placebo-controlled trial. Am Heart J....
Neurology

Double Antithrombotic Therapy Best for PCI Patients With AF

Newsemia
A new network meta-analysis finds that a NOAC plus a P2Y12 inhibitor alone may be the best antiplatelet strategy for these high-risk patients. Medscape Medical...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy